ReviewJournal of clinical medicine2023
Advances of Nanotechnology in the Diagnosis and Treatment of Hepatocellular Carcinoma.
Review in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Seeing beyond words: nanotechnology in hepatocellular carcinoma - a bibliometric study.Frontiers in oncology · 2024Pooled it
- Microfluidics-based Polymeric Micro/Nanocarriers for Drug Delivery in Liver Cancer Treatment: Recent Advances, Outlooks, and Progress.Current topics in medicinal chemistry · 2026Review
- The Application of Nanomaterials in the Detection of Liver Cancer Biomarkers.International journal of nanomedicine · 2026Review
- Potent cytotoxicity and induction of ROS-mediated genomic instability, mitochondrial dysfunction, and apoptosis by YNaunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Modern approach to hepatocellular carcinoma treatment.World journal of hepatology · 2025Review
- Development and optimization of a self micro-emulsifying drug delivery system (SMEDDS) for co-administration of sorafenib and curcumin.Drug delivery and translational research · 2025Article
- Hepatic artery infusion chemotherapy: A resurgence.World journal of gastrointestinal oncology · 2025Article
- Copper(II)-Complexed Polyethylenimine-Entrapped Gold Nanoparticles Enable Targeted CT/MR Imaging and Chemodynamic Therapy of Tumors.Polymers · 2025Article
- Targeted therapy for liver cancer: Current status and future directions.BioImpacts : BI · 2025Review
- Progress in the Application of Novel Nanomaterials in Targeted Therapy for Liver Cancer.International journal of nanomedicine · 2025Review
- Harnessing big data for precision medicine: radiomics based application of nanomaterials in MRI enhancement and multimodal therapy of hepatocellular carcinoma.Frontiers in immunology · 2025Review
- Progress in the Application of Nanobiotechnology in the Ablation Therapy of Hepatic Carcinoma.International journal of nanomedicine · 2025Review
- Nano-Formulations of Natural Antioxidants for the Treatment of Liver Cancer.Biomolecules · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanotechnology has emerged as a promising technology in the field of hepatocellular carcinoma (HCC), specifically in the implementation of diagnosis and treatment strategies. Nanotechnology-based approaches, such as nanoparticle-based contrast agents and nanoscale imaging techniques, have shown great potential for enhancing the sensitivity and specificity of HCC detection. These approaches provide high-resolution imaging and allow for the detection of molecular markers and alterations in cellular morphology associated with HCC. In terms of treatment, nanotechnology has revolutionized HCC therapy by enabling targeted drug delivery, enhancing therapeutic efficacy, and minimizing off-target effects. Nanoparticle-based drug carriers can be functionalized with ligands specific to HCC cells, allowing for selective accumulation of therapeutic agents at the tumor site. Furthermore, nanotechnology can facilitate combination therapy by co-encapsulating multiple drugs within a single nanoparticle, allowing for synergistic effects and overcoming drug resistance. This review aims to provide an overview of recent advances in nanotechnology-based approaches for the diagnosis and treatment of HCC. Further research is needed to optimize the design and functionality of nanoparticles, improve their biocompatibility and stability, and evaluate their long-term safety and efficacy. Nonetheless, the integration of nanotechnology in HCC management holds great promise and may lead to improved patient outcomes in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.